Cardiovascular effects of sodium glucose cotransporter 2 inhibitors

Tricia Santos Cavaiola, Jeremy Pettus Division of Endocrinology and Metabolism, University of California San Diego, San Diego, CA, USA Abstract: As the first cardiovascular (CV) outcome trial of a glucose-lowering agent to demonstrate a reduction in the risk of CV events in patients with type 2 diab...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Santos Cavaiola T, Pettus J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	canagliflozin cardiovascular outcomes dapagliflozin empagliflozin mechanisms sodium glucose cotransporter 2 inhibitors Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/22fde3a5635941f3ab60581c846e8217
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:22fde3a5635941f3ab60581c846e8217
record_format	dspace
spelling	oai:doaj.org-article:22fde3a5635941f3ab60581c846e82172021-12-02T11:07:32ZCardiovascular effects of sodium glucose cotransporter 2 inhibitors1178-7007https://doaj.org/article/22fde3a5635941f3ab60581c846e82172018-04-01T00:00:00Zhttps://www.dovepress.com/cardiovascular-effects-of-sodium-glucose-cotransporter-2-inhibitors-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Tricia Santos Cavaiola, Jeremy Pettus Division of Endocrinology and Metabolism, University of California San Diego, San Diego, CA, USA Abstract: As the first cardiovascular (CV) outcome trial of a glucose-lowering agent to demonstrate a reduction in the risk of CV events in patients with type 2 diabetes mellitus (T2DM), the EMPAgliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME®) trial, which investigated the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, has generated great interest among health care professionals. CV outcomes data for another SGLT2 inhibitor, canagliflozin, have been published recently in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program, as have CV data from the retrospective real-world study Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors (CVD-REAL), which compared SGLT2 inhibitors with other classes of glucose-lowering drugs. This review discusses the results of these three studies and, with a focus on EMPA-REG OUTCOME, examines the possible mechanisms by which SGLT2 inhibitors may reduce CV risk in patients with T2DM. Keywords: canagliflozin, cardiovascular outcomes, dapagliflozin, empagliflozin, mechanisms, sodium glucose cotransporter 2 inhibitorsSantos Cavaiola TPettus JDove Medical Pressarticlecanagliflozincardiovascular outcomesdapagliflozinempagliflozinmechanismssodium glucose cotransporter 2 inhibitorsSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 11, Pp 133-148 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	canagliflozin cardiovascular outcomes dapagliflozin empagliflozin mechanisms sodium glucose cotransporter 2 inhibitors Specialties of internal medicine RC581-951
spellingShingle	canagliflozin cardiovascular outcomes dapagliflozin empagliflozin mechanisms sodium glucose cotransporter 2 inhibitors Specialties of internal medicine RC581-951 Santos Cavaiola T Pettus J Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
description	Tricia Santos Cavaiola, Jeremy Pettus Division of Endocrinology and Metabolism, University of California San Diego, San Diego, CA, USA Abstract: As the first cardiovascular (CV) outcome trial of a glucose-lowering agent to demonstrate a reduction in the risk of CV events in patients with type 2 diabetes mellitus (T2DM), the EMPAgliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME®) trial, which investigated the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, has generated great interest among health care professionals. CV outcomes data for another SGLT2 inhibitor, canagliflozin, have been published recently in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program, as have CV data from the retrospective real-world study Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors (CVD-REAL), which compared SGLT2 inhibitors with other classes of glucose-lowering drugs. This review discusses the results of these three studies and, with a focus on EMPA-REG OUTCOME, examines the possible mechanisms by which SGLT2 inhibitors may reduce CV risk in patients with T2DM. Keywords: canagliflozin, cardiovascular outcomes, dapagliflozin, empagliflozin, mechanisms, sodium glucose cotransporter 2 inhibitors
format	article
author	Santos Cavaiola T Pettus J
author_facet	Santos Cavaiola T Pettus J
author_sort	Santos Cavaiola T
title	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
title_short	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
title_full	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
title_fullStr	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
title_full_unstemmed	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
title_sort	cardiovascular effects of sodium glucose cotransporter 2 inhibitors
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/22fde3a5635941f3ab60581c846e8217
work_keys_str_mv	AT santoscavaiolat cardiovasculareffectsofsodiumglucosecotransporter2inhibitors AT pettusj cardiovasculareffectsofsodiumglucosecotransporter2inhibitors
_version_	1718396217323421696

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors

Ejemplares similares